General Information of Drug (ID: DMF8WAT)

Drug Name
CNTO-5825 Drug Info
Indication
Disease Entry ICD 11 Status REF
Allergic asthma CA23.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMF8WAT

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-13 (IL13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tralokinumab DM6ENSJ Atopic dermatitis EA80 Approved [3]
Lebrikizumab DMQP0X5 Severe asthma CA23 Phase 3 [4]
Dexpramipexole DM6KXAU Eosinophilic asthma CB02.0 Phase 3 [5]
Cendakimab DM9LSBJ Eosinophilic esophagitis DA24.1 Phase 3 [6]
SAR-156597 DMUICJD Idiopathic pulmonary fibrosis CB03.4 Phase 2 [7]
PEGylated pitrakinra DMBPJ9U Asthma CA23 Phase 2 [4]
Romilkimab DMYEZ5J Idiopathic pulmonary fibrosis CB03.4 Phase 2 [8]
QAX-576 DMUWFI7 Allergic rhinitis CA08.0 Phase 2 [9]
Anrukinzumab DMTG2O0 Asthma CA23 Phase 2 [10]
Dectrekumab DM1H7UK Idiopathic pulmonary fibrosis CB03.4 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT01081691) A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers. U.S. National Institutes of Health.
2 Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
5 Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
6 Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
7 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
8 A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
9 Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
10 Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.